PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Peter Borchmann(University of Cologne), Annette Plütschow(University of Cologne), Carsten Kobe(University of Cologne), Richard Greil(University of Salzburg), Julia Meißner(Heidelberg University), Max S. Topp(Universitätsklinikum Würzburg), Helmut Ostermann(Ludwig-Maximilians-Universität München), Judith Dierlamm(University Medical Center Hamburg-Eppendorf), Johannes Mohm, Julia Thiemer(Philipps University of Marburg), Martin Sökler(University Children's Hospital Tübingen), Andrea Kerkhoff(University Hospital Münster), Miriam Ahlborn(Klinikum Braunschweig), Teresa Halbsguth(Goethe University Frankfurt), Sonja Martin(Robert Bosch Hospital), Ulrich Keller(Klinikum rechts der Isar), Stefan Balabanov(University Hospital of Zurich), Thomas Pabst, Martin Vogelhuber(University Hospital Regensburg), Andreas Hüttmann(Essen University Hospital), Martin Wilhelm(Paracelsus Medizinische Privatuniversität), Josée M. Zijlstra(Amsterdam University Medical Centers), Alden A. Moccia(Institute of Oncology Research), Georg Kuhnert(University of Cologne), Paul J. Bröckelmann(University of Cologne), Bastian von Tresckow(University of Duisburg-Essen), Michael Fuchs(University of Cologne), Beate Klimm(Kliniken Maria Hilf), Andreas Rosenwald(Comprehensive Cancer Center Mainfranken), Hans Theodor Eich(University Hospital Münster), Christian Baues(University of Cologne), Simone Marnitz(University of Cologne), Michael Hallek(University of Cologne), Volker Diehl(University of Cologne), Markus Dietlein(University of Cologne), Andreas Engert(University of Cologne)
The Lancet Oncology
February 1, 2021
Cited by 166

Abstract


Related Papers

No related papers found

Powered by citation graph analysis